Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis

References

• Farina N, Benanti G, de Luca G, et al. The role of the multidisciplinary health care team in the management of patients with systemic sclerosis. J Multidiscip Healthc. 2022;15:815–824. doi: 10.2147/JMDH.S295478
   PubMed Web of Science ®Google Scholar
• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–1699. doi: 10.1016/S0140-6736(17)30933-9
   PubMed Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518–2528. doi: 10.1056/NEJMoa1903076
   PubMed Web of Science ®Google Scholar
• Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2021;3(7):e489–e497. doi: 10.1016/S2665-9913(21)00107-7
   PubMedGoogle Scholar
• Khanna D, Bush E, Nagaraja V, et al. Tofacitinib in early diffuse cutaneous systemic sclerosis— results of phase i/ii investigator-initiated, double-blind randomized placebo-controlled trial - ACR meeting abstracts.
   Google Scholar
• Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis. 2011;70(6):1003–1009. doi: 10.1136/ard.2010.143974
   PubMed Web of Science ®Google Scholar
• Gordon J, Udeh U, Doobay K, et al. Imatinib mesylate (Gleevec?) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial. Clin Exp Rheumatol. 2014;32:S–189–93.
   Web of Science ®Google Scholar
• Khanna D, Saggar R, Mayes MD, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011;63(11):3540–3546. doi: 10.1002/art.30548
   PubMedGoogle Scholar
• Prey S, Ezzedine K, Doussau A, et al. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol. 2012;167(5):1138–1144. doi: 10.1111/j.1365-2133.2012.11186.x
   PubMed Web of Science ®Google Scholar
• Gordon JK, Martyanov V, Magro C, et al. Nilotinib (Tasigna™) in the treaTMent of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis Res Ther. 2015;17:17. doi: 10.1186/s13075-015-0721-3
   PubMed Web of Science ®Google Scholar
• Gordon JK, Martyanov V, Franks JM, et al. Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial. Arthritis & Rheumat. 2018;70(2):308–316. doi: 10.1002/art.40358
   PubMed Web of Science ®Google Scholar
• Khanna D, Lin CJF, Furst DE, et al. Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a phase 3 randomized controlled trial. Am J Respir Crit Care Med. 2022;205:674–684. doi: 10.1164/rccm.202103-0714OC
   PubMedGoogle Scholar
• Roofeh D, Lin CJF, Goldin J, et al. Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease. Arthritis & Rheumat 2021;73:1301–1310. doi: 10.1002/art.41668
   PubMed Web of Science ®Google Scholar
• Fukasawa T, Yoshizaki A, Ebata S, et al. Pharmacokinetics, safety, and efficacy of subcutaneous brodalumab for systemic sclerosis with moderate-to-severe skin thickening: a single-arm, open-label, multi-dose, phase 1 Trial - ACR meeting abstracts [Internet]. [cited 2023 Feb 28]. Available from: https://acrabstracts.org/abstract/pharmacokinetics-safety-and-efficacy-of-subcutaneous-brodalumab-for-systemic-sclerosis-with-moderate-to-severe-skin-thickening-a-single-arm-open-label-multi-dose-phase-1-trial/
   Google Scholar
• Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol. 2013;31:151–156.
   PubMed Web of Science ®Google Scholar
• Spiera R, Hummers L, Chung L, et al. Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults with Systemic Sclerosis. Arthritis & Rheumat. 2020;72(8):1350–1360. doi: 10.1002/art.41294
   PubMed Web of Science ®Google Scholar
• Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476–486. doi: 10.1016/S2213-2600(20)30554-3
   PubMed Web of Science ®Google Scholar
• Khanna D, Albera C, Fischer A, et al. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. J Rheumatol. 2016;43(9):1672–1679. doi: 10.3899/jrheum.151322
   PubMed Web of Science ®Google Scholar
• Chung L, Spino C, McLain R, et al. Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatol. 2020;2(12):e743–e753–. doi: 10.1016/S2665-9913(20)30237-X
   PubMedGoogle Scholar
• Khanna D, Spino C, Johnson S, et al. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis & rheumat. 2020;72(1):125–136. doi: 10.1002/art.41055
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(suppl 2):ii111–ii115. doi: 10.1136/annrheumdis-2012-202576
   PubMed Web of Science ®Google Scholar
• Campochiaro C, Allanore Y. An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years. Arthritis Res Ther. 2021;23(1):23. doi: 10.1186/s13075-021-02536-5
   PubMed Web of Science ®Google Scholar
• Pendergrass SA, Hayes E, Farina G, et al. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One. 2010;5(8):e12106. doi: 10.1371/journal.pone.0012106
   PubMed Web of Science ®Google Scholar
• Wang W, Bhattacharyya S, Marangoni RG, et al. The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib. J Scleroderma Relat Disord. 2020;5(1):40–50. doi: 10.1177/2397198319865367
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med. 2020;383(16):1511–1521. doi: 10.1056/NEJMoa2008250
   PubMed Web of Science ®Google Scholar
• Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652–662. doi: 10.1056/NEJMoa1608345
   PubMed Web of Science ®Google Scholar
• Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80(7):848–858. doi: 10.1136/annrheumdis-2020-219214
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(4):316–326. doi: 10.1056/NEJMoa2109927
   PubMed Web of Science ®Google Scholar
• Fujita Y, Nawata M, Nagayasu A, et al. Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: a Novel Case Report. Case Rep Rheumatol. 2019;2019:1–5.
   Google Scholar
• Boleto G, Cren J-B, Avouac J, et al. Successful treatment with baricitinib of refractory arthritis in a patient with severe diffuse cutaneous systemic sclerosis-rheumatoid arthritis overlap syndrome. Clin Exp Rheumatol. 2021;39(131):163–164. doi: 10.55563/clinexprheumatol/gu1ac8
   PubMedGoogle Scholar
• Hudowenz O, Klemm P, Lange U, et al. Widespread soft tissue calcification in systemic sclerosis, polymyositis, and polyarthritis. Lancet. 2021;397(10272):409. doi: 10.1016/S0140-6736(21)00134-3
   PubMed Web of Science ®Google Scholar
• Kitanaga Y, Imamura E, Nakahara Y, et al. In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors. Rheumatology (Oxford). 2020;59(8):1957–1968. doi: 10.1093/rheumatology/kez526
   PubMed Web of Science ®Google Scholar
• Etra AM, Capellini A, Alousi AM, et al. Effective treatment of low-risk acute GVHD with itacitinib monotherapy. Blood. 2023;141(5):481–489. doi: 10.1182/blood.2022017442
   PubMed Web of Science ®Google Scholar
• Knipe RS, Tager AM, Liao JK, et al. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev. 2015;67(1):103–117. doi: 10.1124/pr.114.009381
   PubMed Web of Science ®Google Scholar
• Ali F, Ilyas A. Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease. Curr Res Transl Med. 2022;70:103343. doi: 10.1016/j.retram.2022.103343
   PubMed Web of Science ®Google Scholar
• Akhmetshina A, Dees C, Pileckyte M, et al. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum. 2008;58(8):2553–2564. doi: 10.1002/art.23677
   PubMedGoogle Scholar
• Bei Y, Hua-Huy T, Nicco C, et al. RhoA/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis. Exp Lung Res. 2016;42(1):44–55. doi: 10.3109/01902148.2016.1141263
   PubMed Web of Science ®Google Scholar
• Zhou Y, Huang X, Hecker L, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest. 2013;123(3):1096–1108. doi: 10.1172/JCI66700
   PubMed Web of Science ®Google Scholar
• Brown M, O’Reilly S. The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol. 2019;195(3):310–321. doi: 10.1111/cei.13238
   PubMed Web of Science ®Google Scholar
• Dees C, Pötter S, Zhang Y, et al. TGF-β-induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis. J Clin Invest. 2020;130:2347–2363. doi: 10.1172/JCI122462
   PubMed Web of Science ®Google Scholar
• Lomelí-Nieto JA, Muñoz-Valle JF, Baños-Hernández CJ, et al. Transforming growth factor beta isoforms and TGF-βR1 and TGF-βR2 expression in systemic sclerosis patients. Clin Exp Med. 2022;23(2):471–481. doi: 10.1007/s10238-022-00841-0
   PubMed Web of Science ®Google Scholar
• Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford). 2008;47(5):v2–v4. doi: 10.1093/rheumatology/ken265
   PubMedGoogle Scholar
• Svegliati Baroni S, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006;354(25):2667–2676. doi: 10.1056/NEJMoa052955
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target. Mol Aspects Med. 2018;62:75–88. doi: 10.1016/j.mam.2017.11.007
   PubMed Web of Science ®Google Scholar
• Denton CP, Merkel PA, Furst DE, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 2007;56:323–333. doi: 10.1002/art.22289
   PubMed Web of Science ®Google Scholar
• Karimizadeh E, Motamed N, Mahmoudi M, et al. Attenuation of fibrosis with selective inhibition of c-Abl by siRNA in systemic sclerosis dermal fibroblasts. Arch Dermatol Res. 2015;307(2):135–142. doi: 10.1007/s00403-014-1532-0
   PubMed Web of Science ®Google Scholar
• Karimizadeh E, Gharibdoost F, Motamed N, et al. C-Abl silencing reduced the inhibitory effects of TGF-β1 on apoptosis in systemic sclerosis dermal fibroblasts. Mol Cell Biochem. 2015;405(1–2):169–176. doi: 10.1007/s11010-015-2408-0
   PubMed Web of Science ®Google Scholar
• Waller CF. Imatinib Mesylate. Recent Results Cancer Res. 2018;212:1–27.
   PubMedGoogle Scholar
• Nagar B. C-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571). J Nutr. 2007;137(6):1518S–1523S. doi: 10.1093/jn/137.6.1518S
   PubMed Web of Science ®Google Scholar
• Hinchcliff M, Huang CC, Ishida W, et al. Imatinib Mesylate Causes Genome-wide Transcriptional Changes in Systemic Sclerosis Fibroblasts in vitro. Clin Exp Rheumatol. 2012;30:S86.
   PubMed Web of Science ®Google Scholar
• Bournia VK, Evangelou K, Sfikakis PP. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib. Semin Arthritis Rheum. 2013;42(4):377–390. doi: 10.1016/j.semarthrit.2012.06.001
   PubMed Web of Science ®Google Scholar
• Liakouli V, Ciaffi J, Ursini F, et al. Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis. Expert Rev Clin Immunol. 2020;16(9):931–942. doi: 10.1080/1744666X.2020.1813569
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540–3546. doi: 10.1182/blood-2007-03-080689
   PubMed Web of Science ®Google Scholar
• Manley PW, Drueckes P, Fendrich G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804(3):445–453. doi: 10.1016/j.bbapap.2009.11.008
   PubMed Web of Science ®Google Scholar
• Akhmetshina A, Dees C, Pileckyte M, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. Faseb J. 2008;22(7):2214–2222. doi: 10.1096/fj.07-105627
   PubMed Web of Science ®Google Scholar
• Xue M, Cao X, Zhong Y, et al. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives. Curr Pharm Des. 2012;18(20):2901–2913. doi: 10.2174/138161212800672723
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Fujimoto M, Matsushita T, et al. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis. J Rheumatol. 2008;35(12):2363–2371. doi: 10.3899/jrheum.080340
   PubMed Web of Science ®Google Scholar
• Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med. 2020 [[cited 2023 Feb 5]];382:341–352. InternetAvailable from https://pubmed.ncbi.nlm.nih.gov/31971679/
   PubMed Web of Science ®Google Scholar
• Yap DYH, Chan TM. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis—Role in Pathogenesis and Effect of Immunosuppressive Treatments. Int J Mol Sci. 2019;20:20. doi: 10.3390/ijms20246231
   Web of Science ®Google Scholar
• Liem SIE, Neppelenbroek S, Fehres CM, et al. Autoreactive B cell responses targeting nuclear antigens in systemic sclerosis: implications for disease pathogenesis. Semin Arthritis Rheum. 2023;58:152136. doi: 10.1016/j.semarthrit.2022.152136
   PubMed Web of Science ®Google Scholar
• Morgan K, Woollard C, Beinart D, et al. Rituximab treatment for systemic sclerosis-associated interstitial lung disease: a case series of 13 patients. Intern Med J. 2022. doi:10.1111/imj.15832.
   Web of Science ®Google Scholar
• Maher TM, Tudor VA, Saunders P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023 [[cited 2023 Feb 28]];11:45–54. InternetAvailable from https://pubmed.ncbi.nlm.nih.gov/36375479/
   PubMed Web of Science ®Google Scholar
• Schiopu E, Chatterjee S, Hsu V, et al. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther. 2016;18(1): doi: 10.1186/s13075-016-1021-2
   Google Scholar
• Streicher K, Sridhar S, Kuziora M, et al. Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment with Inebilizumab (MEDI-551) and Correlates with Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease. Arthritis & Rheumat. 2018;70(12):2087–2095. doi: 10.1002/art.40656
   PubMed Web of Science ®Google Scholar
• Malysz J, Erdman P, Klapper J, et al. Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas. Clin Lymphoma Myeloma Leuk. 2016;16(8):429–433. doi: 10.1016/j.clml.2016.04.011
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Cipriani P, Lattanzio R, et al. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol. 2003;108(1):42–46. doi: 10.1046/j.1365-2249.1997.d01-991.x
   Google Scholar
• Furie R, Rovin BH, Houssiau F, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020;383(12):1117–1128. doi: 10.1056/NEJMoa2001180
   PubMed Web of Science ®Google Scholar
• Shipa M, Embleton-Thirsk A, Parvaz M, et al. Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus: a Randomized Controlled Trial. Ann Intern Med. 2021;174(12):1647–1657. doi: 10.7326/M21-2078
   PubMed Web of Science ®Google Scholar
• de Luca G, Cavalli G, Campochiaro C, et al. Interleukin-1 and Systemic Sclerosis: getting to the Heart of Cardiac Involvement. Front Immunol. 2021;12:12. doi: 10.3389/fimmu.2021.653950
   Web of Science ®Google Scholar
• O’Reilly S, Cant R, Ciechomska M, et al. Interleukin-6: a new therapeutic target in systemic sclerosis? Clin Transl Immunology. 2013;2(4):e4. doi: 10.1038/cti.2013.2
   PubMedGoogle Scholar
• Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSscinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630–2640. doi: 10.1016/S0140-6736(16)00232-4
   PubMed Web of Science ®Google Scholar
• FDA. Highlights of prescribing information of Actemra.
   Google Scholar
• Rafael-Vidal C, Pérez N, Altabás I, et al. Blocking IL-17: a Promising Strategy in the Treatment of Systemic Rheumatic Diseases. Int J Mol Sci. 2020;21:1–14. doi: 10.3390/ijms21197100
   Web of Science ®Google Scholar
• Lei L, Zhao C, Qin F, et al. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis. Clin Exp Rheumatol. 2016;34(100):14–22.
   PubMedGoogle Scholar
• Wei L, Abraham D, Ong V. The Yin and Yang of IL-17 in Systemic Sclerosis. Front Immunol. 2022;13: doi: 10.3389/fimmu.2022.885609
   Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015;373(14):1318–1328. doi: 10.1056/NEJMoa1503824
   PubMed Web of Science ®Google Scholar
• Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10):612–632. doi: 10.1038/s41584-019-0277-8
   PubMed Web of Science ®Google Scholar
• De Luca G, Cavalli G, Campochiaro C, et al. Myocarditis: an Interleukin-1-Mediated Disease? Front Immunol. 2018;9:1335. doi: 10.3389/fimmu.2018.01335
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Immunological and Inflammatory Functions of the Interleukin-1 Family. Annu Rev Immunol. 2009;27(1):519–550. doi: 10.1146/annurev.immunol.021908.132612
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720–3732. doi: 10.1182/blood-2010-07-273417
   PubMed Web of Science ®Google Scholar
• Xu D, Mu R, Wei X. The Roles of IL-1 Family Cytokines in the Pathogenesis of Systemic Sclerosis. Front Immunol. 2019;10: doi: 10.3389/fimmu.2019.02025
   Web of Science ®Google Scholar
• Higgins GC, Wu Y, Postlethwaite AE. Intracellular IL-1 receptor antagonist is elevated in human dermal fibroblasts that overexpress intracellular precursor IL-1α. J Immunol. 1999;163(7):3969–3975. doi: 10.4049/jimmunol.163.7.3969
   PubMed Web of Science ®Google Scholar
• Hussein MR, Hassan HI, Hofny ERM, et al. Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1β, and tumour necrosis factor α in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol. 2005;58:178–184. doi: 10.1136/jcp.2004.019224
   PubMed Web of Science ®Google Scholar
• Martínez-Godínez MA, Del P C-DM, Jara LJ, et al. Expression of NLRP3 inflammasome, cytokines and vascular mediators in the skin of systemic sclerosis patients. Isr Med Assoc J. 2015;17(1):5–10.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Natsis NE, Kerdel F, et al. A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain. J Invest Dermatol. 2020 [[cited 2023 Feb 5]];140:1538–1545.e2. InternetAvailable from https://pubmed.ncbi.nlm.nih.gov/32004568/
   PubMed Web of Science ®Google Scholar
• Komura K, Fujimoto M, Hasegawa M, et al. Increased Serum Interleukin 23 in Patients with Systemic Sclerosis. J Rheumatol. 2008;35:2359–2362. doi: 10.3899/jrheum.080120
   PubMed Web of Science ®Google Scholar
• Senoo S, Taniguchi A, Itano J, et al. Essential role of IL-23 in the development of acute exacerbation of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2021;321(5):L925–L940. doi: 10.1152/ajplung.00582.2020
   PubMed Web of Science ®Google Scholar
• Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115–1125. doi: 10.1016/S0140-6736(20)30265-8
   PubMed Web of Science ®Google Scholar
• Kuzumi A, Yoshizaki A, Matsuda KM, et al. Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. Nat Commun. 2021;12(1):12. doi: 10.1038/s41467-021-26099-w
   PubMed Web of Science ®Google Scholar
• Ständer S, Yosipovitch G, Legat FJ, et al. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. N Engl J Med. 2020;382(8):706–716. doi: 10.1056/NEJMoa1908316
   PubMed Web of Science ®Google Scholar
• SJ K. Nemolizumab: first Approval. Drugs. 2022;82:1143–1150. doi: 10.1007/s40265-022-01741-z
   PubMedGoogle Scholar
• Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology–mode of action and clinical efficacy. Nat Rev Neurol. 2015;11:80–89. doi: 10.1038/nrneurol.2014.253
   PubMed Web of Science ®Google Scholar
• Hoffmann JHO, Enk AH. High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease. Front Immunol. 2019;10:10. doi: 10.3389/fimmu.2019.01090
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Charles-Schoeman C, Schessl J, et al. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med. 2022;387(14):1264–1278. doi: 10.1056/NEJMoa2117912
   PubMed Web of Science ®Google Scholar
• Molina V, Haj-Yahia S, Solodeev I, et al. Immunomodulation of experimental pulmonary fibrosis by intravenous immunoglobulin (IVIG). Autoimmunity. 2006;39(8):711–717. doi: 10.1080/08916930601061272
   PubMed Web of Science ®Google Scholar
• Blank M, Levy Y, Amital H, et al. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum. 2002;46(6):1689–1690. doi: 10.1002/art.10363
   PubMed Web of Science ®Google Scholar
• Levy Y, Sherer Y, Langevitz P, et al. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin–a preliminary report. Clin Rheumatol. 2000;19:207–211. doi: 10.1007/s100670050158
   PubMed Web of Science ®Google Scholar
• Agostini E, de Luca G, Bruni C, et al. Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. Autoimmun Rev. 2021;20(12):20. doi: 10.1016/j.autrev.2021.102981
   Web of Science ®Google Scholar
• Clark KEN, Etomi O, Denton CP, et al. Intravenous immunoglobulin therapy for severe gastrointestinal involvement in systemic sclerosis. Clin Exp Rheumatol. 2015;33:168–170.
   PubMed Web of Science ®Google Scholar
• Mauhin W, Rivière S, Cabane J, et al. Improvement in lung fibrosis using intravenous immunoglobulin in systemic sclerosis with myositis. Scand J Rheumatol. 2014;43(2):170–171. doi: 10.3109/03009742.2013.868510
   PubMed Web of Science ®Google Scholar
• Garcia-Gonzalez E, Selvi E, Balistreri E, et al. Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts. Rheumatology (Oxford). 2009;48(9):1050–1056. doi: 10.1093/rheumatology/kep189
   PubMed Web of Science ®Google Scholar
• García-Martín A, Garrido-Rodríguez M, Navarrete C, et al. EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis. Biochem Pharmacol. 2018;157:304–313. doi: 10.1016/j.bcp.2018.07.047
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769. doi: 10.1016/S0140-6736(11)60405-4
   PubMed Web of Science ®Google Scholar
• Xiao H, Zhang GF, Liao XP, et al. Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease. Int J Rheum Dis. 2018;21(2):477–486. doi: 10.1111/1756-185X.13247
   PubMed Web of Science ®Google Scholar
• Khanna D, Spino C, Bernstein E, et al. Combination Therapy of Mycophenolate Mofetil and Pirfenidone vs. Mycophenolate Alone: results from the Scleroderma Lung Study III - ACR Meeting Abstracts [Internet].
   Google Scholar
• Varricchio L, Iancu-Rubin C, Upadhyaya B, et al. TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis. JCI Insight. 2021;6(18):6. doi: 10.1172/jci.insight.145651
   Web of Science ®Google Scholar
• Xie S, Li S, Tian J, et al. Iguratimod as a New Drug for Rheumatoid Arthritis: current Landscape. Front Pharmacol. 2020;11:11. doi: 10.3389/fphar.2020.00073
   PubMed Web of Science ®Google Scholar
• Mu R, Li C, Li X, et al. Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: a nationwide, prospective real-world study. Lancet Reg Health West Pac. 2021;10:100128.
   Google Scholar
• Shu P, Shao SQ, Cai XN, et al. Iguratimod attenuates general disease activity and improves lung function in rheumatoid arthritis-associated interstitial lung disease patients. Eur Rev Med Pharmacol Sci. 2021;25(14):4687–4692. doi: 10.26355/eurrev_202107_26379
   PubMed Web of Science ®Google Scholar
• Lin H, Wu C, Zhu F, et al. Anti-fibrotic effect of iguratimod on pulmonary fibrosis by inhibiting the fibroblast-to-myofibroblast transition. Adv Med Sci. 2020;65:338–347. doi: 10.1016/j.advms.2020.05.006
   PubMed Web of Science ®Google Scholar
• Zhao L, Mu B, Zhou R, et al. Iguratimod ameliorates bleomycin-induced alveolar inflammation and pulmonary fibrosis in mice by suppressing expression of matrix metalloproteinase-9. Int J Rheum Dis. 2019;22(4):686–694. doi: 10.1111/1756-185X.13463
   PubMed Web of Science ®Google Scholar
• Xie X, Gan H, Tian J, et al. Iguratimod inhibits skin fibrosis by regulating TGF-β1/Smad signalling pathway in systemic sclerosis. Eur J Clin Invest. 2022;52(8): doi: 10.1111/eci.13791
   Web of Science ®Google Scholar
• Wang W, Guo DY, Lin YJ, et al. Melanocortin Regulation of Inflammation. Front Endocrinol. 2019;10:683.
   PubMed Web of Science ®Google Scholar
• Wolf Horrell EM, Boulanger MC, D’Orazio JA. Melanocortin 1 Receptor: structure, Function, and Regulation. Front Genet. 2016;7: doi: 10.3389/fgene.2016.00095
   PubMed Web of Science ®Google Scholar
• Kokot A, Sindrilaru A, Schiller M, et al. Alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma? Arthritis Rheum. 2009;60:592–603. doi: 10.1002/art.24228
   PubMed Web of Science ®Google Scholar
• Kondo M, Suzuki T, Kawano Y, et al. Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis. Arthritis Res Ther. 2022;24(1):24. doi: 10.1186/s13075-022-02899-3
   PubMed Web of Science ®Google Scholar
• Xu WD, Li R, Huang AF. Role of TL1A in Inflammatory Autoimmune Diseases: a Comprehensive Review. Front Immunol. 2022;13: doi: 10.3389/fimmu.2022.891328
   Google Scholar
• Danese S, Klopocka M, Scherl EJ, et al. Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: a Phase 2a Single-Arm Study. Clin Gastroenterol Hepatol. 2021;19(11):2324–2332.e6. doi: 10.1016/j.cgh.2021.06.011
   PubMed Web of Science ®Google Scholar
• Herro R, Miki H, Sethi GS, et al. TL1A Promotes Lung Tissue Fibrosis and Airway Remodeling. J Immunol. 2020;205(9):2414–2422. doi: 10.4049/jimmunol.2000665
   PubMed Web of Science ®Google Scholar
• Xu W, Su L, Qing P, et al. Elevated levels of TL1A are associated with disease activity in patients with systemic sclerosis. Clin Rheumatol. 2017;36(6):1317–1324. doi: 10.1007/s10067-017-3612-y
   PubMed Web of Science ®Google Scholar
• Tsou PS, Talia NN, Pinney AJ, et al. Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts. Arthritis Rheum. 2012;64(6):1978–1989. doi: 10.1002/art.34336
   PubMedGoogle Scholar
• Morrow JD. The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev. 2000;32:377–385. doi: 10.1081/DMR-100102340
   PubMed Web of Science ®Google Scholar
• Tsou PS, Amin MA, Campbell PL, et al. Activation of the Thromboxane A2 Receptor by 8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Scleroderma. J Invest Dermatol. 2015;135(12):3153–3162. doi: 10.1038/jid.2015.323
   PubMed Web of Science ®Google Scholar
• Katz SD, Radin M, Graves T, et al. Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with enalapril. J Am Coll Cardiol. 1999;34(1):170–176. doi: 10.1016/S0735-1097(99)00180-1
   PubMed Web of Science ®Google Scholar
• Suzuki T, Kropski JA, Chen J, et al. Thromboxane-Prostanoid Receptor Signaling Drives Persistent Fibroblast Activation in Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022;206:596–607. doi: 10.1164/rccm.202106-1503OC
   PubMed Web of Science ®Google Scholar
• Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996;65(1):801–847. doi: 10.1146/annurev.bi.65.070196.004101
   PubMedGoogle Scholar
• Krüger E, Kloetzel PM. Immunoproteasomes at the interface of innate and adaptive immune responses: two faces of one enzyme. Curr Opin Immunol. 2012;24(1):77–83. doi: 10.1016/j.coi.2012.01.005
   PubMed Web of Science ®Google Scholar
• Limanaqi F, Biagioni F, Gaglione A, et al. A Sentinel in the Crosstalk Between the Nervous and Immune System: the (Immuno)-Proteasome. Front Immunol. 2019;10:10. doi: 10.3389/fimmu.2019.00628
   PubMed Web of Science ®Google Scholar
• Verbrugge EE, Scheper RJ, Lems WF, et al. Proteasome inhibitors as experimental therapeutics of autoimmune diseases. Arthritis Res Ther. 2015;17:17. doi: 10.1186/s13075-015-0529-1
   PubMed Web of Science ®Google Scholar
• Yoon B, Yun Y, Kim KB, et al. Inhibition of immunoproteasome attenuates NLRP3 inflammasome formation in tumor necrosis factor α-stimulated intestinal epithelial cell. Biochem Biophys Res Commun. 2022;624:157–163. doi: 10.1016/j.bbrc.2022.07.120
   PubMed Web of Science ®Google Scholar
• Del Rio Oliva M, Mellett M, Basler M. Immunoproteasome inhibition attenuates experimental psoriasis. Front Immunol. 2022;13: doi: 10.3389/fimmu.2022.1075615
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;374(17):1621–1634. doi: 10.1056/NEJMoa1516282
   PubMed Web of Science ®Google Scholar
• Fernández-Díaz C, Castañeda S, Melero-González RB, et al. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. Rheumatology (Oxford). 2020;59(12):3906–3916. doi: 10.1093/rheumatology/keaa621
   PubMed Web of Science ®Google Scholar
• Kalogerou A, Gelou E, Mountantonakis S, et al. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis. 2005;64:1233–1235. doi: 10.1136/ard.2004.027094
   PubMed Web of Science ®Google Scholar
• Ponsoye M, Frantz C, Ruzehaji N, et al. Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. Ann Rheum Dis. 2016;75(12):2142–2149. doi: 10.1136/annrheumdis-2015-208213
   PubMed Web of Science ®Google Scholar
• Chakravarty EF, Martyanov V, Fiorentino D, et al. Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. Arthritis Res Ther. 2015;17(1):17. doi: 10.1186/s13075-015-0669-3
   PubMedGoogle Scholar